Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Payables (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Payables for 5 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 54.88% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Dec 2025, up 54.88%, and an annual FY2025 reading of $4.0 million, up 54.88% over the prior year.
  • Payables was $4.0 million for Q4 2025 at Aligos Therapeutics, down from $4.7 million in the prior quarter.
  • Across five years, Payables topped out at $6.8 million in Q2 2024 and bottomed at $1.6 million in Q2 2021.
  • Average Payables over 5 years is $3.4 million, with a median of $2.9 million recorded in 2022.
  • The sharpest move saw Payables tumbled 46.87% in 2023, then soared 110.4% in 2024.
  • Year by year, Payables stood at $3.0 million in 2021, then surged by 57.11% to $4.7 million in 2022, then crashed by 46.87% to $2.5 million in 2023, then increased by 2.15% to $2.6 million in 2024, then surged by 54.88% to $4.0 million in 2025.
  • Business Quant data shows Payables for ALGS at $4.0 million in Q4 2025, $4.7 million in Q3 2025, and $3.9 million in Q2 2025.